Lurbinectedin + Durvalumab for Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether a combination of two drugs, lurbinectedin and durvalumab, can benefit people with extensive stage small cell lung cancer (ES-SCLC) whose cancer remains stable after initial treatment. The trial aims to determine if this drug combination is safe and effective in halting cancer growth. It targets individuals who have already undergone a specific type of chemotherapy and are otherwise in good health, with no current lung or brain issues. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, providing an opportunity to contribute to significant findings.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that the combination of lurbinectedin and durvalumab is generally well-tolerated for treating small cell lung cancer. While side effects occur, they are usually manageable and not severe for most patients.
Lurbinectedin has been used in patients with advanced small cell lung cancer, and results support its use as a treatment option. Studies on its combination with durvalumab suggest it does not significantly increase the risk of serious side effects. Overall, the safety data indicate that this treatment is promising for patients, though more research is needed to confirm long-term safety.12345Why are researchers excited about this trial's treatments?
Researchers are excited about the combination of durvalumab and lurbinectedin for treating small cell lung cancer because it offers a new approach compared to the standard chemotherapy options like platinum-based drugs and etoposide. Durvalumab is an immune checkpoint inhibitor that helps the immune system better detect and attack cancer cells. Lurbinectedin, on the other hand, interferes with the cancer cells' ability to replicate DNA, thereby preventing their growth. This dual-action strategy of boosting immune response while directly targeting cancer cell replication holds promise for improved outcomes in patients with this aggressive cancer type.
What evidence suggests that this trial's treatments could be effective for small cell lung cancer?
Research has shown that using lurbinectedin with durvalumab may help treat extensive-stage small cell lung cancer (ES-SCLC). In this trial, participants will receive a combination of durvalumab and lurbinectedin after first-line induction therapy. Studies have found that lurbinectedin, when used as a second treatment option, can extend patients' lives and is generally safe. In everyday medical practice, it has effectively treated patients whose cancer has returned. Durvalumab boosts the immune system to fight cancer cells. Together, these drugs aim to control the cancer and improve outcomes after the first round of treatment, offering hope for patients with ES-SCLC.24567
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Induction Treatment
Participants receive 4 cycles of durvalumab and platinum plus etoposide containing regimen
Maintenance Treatment
Participants receive lurbinectedin in combination with durvalumab as maintenance therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Durvalumab
- Lurbinectedin
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Durvalumab taken in combination with lurbinectedin in participants with ES-SCLC after first line induction therapy with durvalumab and platinum plus etoposide containing regimen.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jazz Pharmaceuticals
Lead Sponsor
Bruce C. Cozadd
Jazz Pharmaceuticals
Chief Executive Officer since 2009
BA in Economics from Yale University, MBA from Stanford University
Dr. Austin
Jazz Pharmaceuticals
Chief Medical Officer since 2023
MD from the Royal College of Surgeons in Ireland
Jazz Pharmaceuticals Ireland Limited
Industry Sponsor
Citations
Current insights and future prospects—A systematic review.
Conclusions: LUR-IO shows promising efficacy and manageable safety profiles in extensive-stage small-cell lung cancer. However, further results ...
NCT07459634 | A Study of Lurbinectedin in Combination ...
The study will evaluate the safety and efficacy of lurbinectedin in combination with durvalumab as maintenance therapy in participants with ES-SCLC after first ...
Real-World Outcomes With Lurbinectedin in Second-Line ...
Lurbinectedin is a valid treatment option for patients with relapsed small cell lung cancer (SCLC) according to current management guidelines. •. This real- ...
Lurbinectedin Maintenance Yields Improved Survival in ES ...
During a live event, Tejas Patil, MD, discussed outcomes from small cell lung cancer trials including the recent IMforte study.
small cell lung cancer (ES-SCLC): real world response ...
This study aims to analyze the line-specific outcomes, duration of response patterns, and the impact of prior therapies on lurbinectedin effectiveness in SCLC, ...
Outcome and safety of lurbinectedin as compassionate use ...
Lurbinectedin has recently emerged in the treatment landscape of extensive stage (ES) small cell lung cancer (SCLC). Here we report the outcomes ...
Outcome and safety of lurbinectedin as compassionate use ...
Lurbinectedin represents a therapeutic option as compassionate use in patients with ES-SCLC, especially in those with a long CFI.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.